WEBULL

Should Teva’s Q3 Beat and New Schizophrenia and Denosumab Moves Require Action From TEVA Investors?

Simply Wall St · 01/08 20:39
  • Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analyst expectations, advanced its pipeline with a U.S. FDA New Drug Application for an olanzapine long-acting injectable for schizophrenia, and secured European Commission approval to market denosumab biosimilars.
  • Alongside these regulatory milestones, Teva’s upcoming CEO presentation at the J.P. Morgan Healthcare Conference underscores its push toward becoming an innovative biopharmaceutical company built on a large generics base.
  • We’ll now examine how Teva’s recent olanzapine and denosumab pipeline progress may influence the company’s investment narrative and outlook.

Find companies with promising cash flow potential yet trading below their fair value.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe it can keep shifting from a challenged generics player to a steadier, higher-margin biopharma business while managing its US$15 billion-plus debt load. The recent FDA filing for long-acting olanzapine and EU approval for denosumab biosimilars are incremental positives, but they do not fundamentally change the near term execution risk around the pipeline or the reliance on a handful of branded drugs for growth.

The European Commission approval for denosumab biosimilars is particularly relevant, because it directly tests Teva’s ability to turn its biosimilar pipeline into tangible revenue while its traditional generics segment faces flat to low single digit growth. How quickly physicians, payers and patients adopt these products, especially against entrenched competitors, will be an early signal of whether biosimilars can offset pressure on the base business and support the biopharma transition.

But investors should be aware that heavy debt and uncertain biosimilar uptake could still...

Read the full narrative on Teva Pharmaceutical Industries (it's free!)

Teva Pharmaceutical Industries' narrative projects $17.8 billion revenue and $1.5 billion earnings by 2028. This requires 2.3% yearly revenue growth and about a $1.7 billion earnings increase from $-157.0 million today.

Uncover how Teva Pharmaceutical Industries' forecasts yield a $33.86 fair value, a 5% upside to its current price.

Exploring Other Perspectives

TEVA 1-Year Stock Price Chart
TEVA 1-Year Stock Price Chart

Fourteen members of the Simply Wall St Community currently see Teva’s fair value between US$26.31 and US$70.03, highlighting very different expectations. Set this against Teva’s reliance on a few branded drugs for growth, and you can see why it may be worth weighing several contrasting views on how resilient that earnings engine really is.

Explore 14 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth over 2x more than the current price!

Build Your Own Teva Pharmaceutical Industries Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.